Companies are employing AI to respond to the Covid-19 pandemic in a number of different ways, including diagnosing Covid-19 cases, identifying which patients would be at highest risk and discovering potential treatments. But not all of these approaches have been validated, experts warned.
Numerous emerging companies aim to fix America's broken healthcare system. How can we differentiate between solving the issue and contributing to the system's existing fragmentation?
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
GE Ventures led the $10.8 million Series A investment, joined by Greycroft Partners, Flare Capital Partners and Manatt Ventures.